Pleon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pleon

What is Pleon? Overview and Quick Facts

Pleon is a complex multi-component pharmaceutical preparation defined by its seven active ingredients. It functions as a metabolic regulator and a cellular trophic agent to support the body's essential metabolic processes.

Property Description
Active Ingredients Adenine, Carnitine Orotate, Fructose Diphosphate Magnesium, Potassium Orotate, Sulfasalazine, Vitamin B Substances, Xanthine
Pharmacological Class Metabolic Regulator, Cellular Trophic Agent, Immunological Modulator
Origin Combination of naturally occurring metabolites/vitamins and synthetic compounds
Type Complex Combination Product (Requires Prescription Status)

Definition and Pharmacological Classification

Pleon is a systemic, multi-component combination product that is clinically recognized for its specialized, broad-spectrum approach to cellular support. It is classified primarily as a metabolic regulator because its components are integral to energy cycles and nucleic acid synthesis. This focus on core biochemical processes, combined with the presence of an immunomodulating agent, places it in a specialized class of cellular trophic agents. A key component, Sulfasalazine, is a well-established anti-inflammatory drug used to manage specific immune conditions, confirming Pleon's dual action in metabolic support and targeted modulation.


Composition and General Purpose

The composition of Pleon is notable for blending key naturally occurring metabolites (like Adenine and Carnitine) with pharmaceutical synthetic compounds (like Orotates and Sulfasalazine). The formulation supplies precursors like Adenine and Xanthine for DNA and RNA synthesis, and vital co-factors (Vitamin B Substances) necessary for numerous enzyme systems. The overall general purpose of this assembly is to provide intensive metabolic and cellular support and assist the body in maintaining or restoring function during states of physiological stress. Multi-nutrient approaches suggest that supplying these cellular components can enhance the efficiency of metabolic rescue pathways. This indicates the drug is fundamentally designed to optimize cell function and repair, a mechanism supported by pharmacological studies on metabolic precursors.

What side effects are possible with Pleon?

Possible Side Effects and Safety Information

The officially documented adverse reaction profile for Pleon is primarily governed by the established regulatory data of its key component, Sulfasalazine. Safety information is organized by government authorities based on the frequency and the System-Organ Class (SOC) affected, adhering to regulatory classification standards.


Frequency-Classified Adverse Reactions

Adverse reactions are classified according to their official likelihood:

  • Very Common (ge 1/10): Headache and Anorexia (loss of appetite).
  • Common (1/100 to <1/10): Dizziness, Nausea, Vomiting, Abdominal pain or gastric distress, and Fever.

System-Organ Class Safety Groups

The label documents effects across multiple systems, including Blood and Lymphatic System Disorders (e.g., Agranulocytosis, Aplastic Anemia), Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders (liver damage).


Serious Adverse Reactions and Safety Constraints

Official regulatory documents highlight serious adverse reactions that are rare but clinically significant. These include severe Blood Dyscrasias, severe Cutaneous Reactions (such as Stevens-Johnson Syndrome), and systemic Hypersensitivity Reactions.

The use of Pleon is officially restricted (contraindicated) for individuals with known hypersensitivity to Sulfasalazine, Sulfonamides, or Salicylates, and in patients with severe hepatic or renal impairment or a diagnosis of Porphyria. Furthermore, the official label notes that the risk for serious events, including severe cutaneous reactions, appears to be highest during the first few months of therapy.

This structured safety profile ensures that all potential risks, from the most common non-serious effects to rare, life-threatening events, are formally categorized and communicated.

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived strictly from government regulatory documentation regarding the drug's official overdose profile.

Element Regulatory Statement
Documented Overdose Presentations Clinical manifestations include Gastrointestinal distress (Nausea, Vomiting, Abdominal pains), CNS symptoms (Drowsiness, Convulsions), and Crystalluria (crystals in the urine).
Physiological Systems Affected Primarily Gastrointestinal, Central Nervous System, and Renal systems, with potential for severe Hematologic effects.
Emergency-Response Statements Management is defined as symptomatic and supportive. No specific antidote is known. Procedures may include Gastric lavage or Emesis plus catharsis, and Alkalinizing the urine with Forced fluids if kidney function is normal.

Serious outcomes listed in regulatory documents include irreversible CNS changes, complete renal blockage by crystals, and severe blood dyscrasias. Patients must seek medical advice immediately upon the occurrence of signs potentially indicating serious toxicity, such as Fever, Pallor, Purpura, or Jaundice. Monitoring progress requires assessing Serum sulfapyridine concentrations and conducting frequent Complete blood counts and Urinalysis. Caution is noted for patients with pre-existing Hepatic or Renal Damage, as fluid restriction is mandated if Anuria is present.

Therapeutic Uses of Pleon

What Pleon Treats: Main Uses and Benefits

Pleon is a specialized combination product indicated for use in clinical settings involving systemic and inflammatory conditions, focusing on sustained symptom control in conditions characterized by periods of heightened symptoms.

Managing Inflammatory and Metabolic Symptoms

Pleon is used to help manage the symptoms related to inflammatory or irritative states found in chronic conditions. This includes Rheumatoid Arthritis (in adult and certain pediatric forms) and Ulcerative Colitis (specifically mild to moderate disease activity). By addressing the underlying inflammatory process, the medication may assist with reducing symptoms related to physical discomfort like joint swelling and pain.

The medication also supports symptoms that create noticeable physiological strain or functional deficits due to chronic illness. This supportive therapy contributes to improved comfort and assists with maintaining functional stability during symptomatic periods. This treatment is relevant for easing overall distress and reducing the overall symptom load.


Quick Fact: Relief for Chronic Discomfort

Pleon is commonly used to help manage symptom clusters that may become intense or disruptive in conditions involving inflammatory or irritative processes.

Regulatory References

  1. NIH MedlinePlus Drug Information on Sulfasalazine

Eligibility and Restrictions for Use

Who can and cannot use Pleon?

The eligibility profile for Pleon is strictly defined by regulatory guidelines, focusing on absolute contraindications, organ function, and patient demographics.

Contraindicated Populations

The medicine must not be used by patients with a documented hypersensitivity to sulfasalazine, sulfonamides, or salicylates. Use is also prohibited in individuals with porphyria or with pre-existing intestinal or urinary obstruction. Consistent with regulatory guidance, Pleon is contraindicated in infants under two years of age.

Conditional Use and Age Rules

While use is established for adults and children aged six years and older for certain labeled conditions, safety and efficacy are not established for children under six. Use requires critical appraisal for populations with non-severe hepatic damage, renal damage, or blood dyscrasias. Special caution is also noted for patients with severe allergy or bronchial asthma.

Pregnancy and Lactation Status

Pleon is generally permitted during pregnancy if clearly needed (US FDA Category B), but requires mandatory high-dose folic acid supplementation due to the drug’s potential to inhibit folate absorption. Use during lactation requires caution, and monitoring of the infant is advised.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Pleon, based on regulatory documentation for its key active component, Sulfasalazine, includes specific constraints regarding co-administration and effects on other substances. This information is derived from government-approved labeling.

Mandatory Restrictions and Pharmacodynamic Risks

Co-administration with the urinary antiseptic Methenamine is officially prohibited. This combination is formally contraindicated due to the documented risk of insoluble precipitate formation within the urine.

The regulatory profile highlights an increased pharmacodynamic risk when Pleon is combined with the immunosuppressants Azathioprine or 6-Mercaptopurine. This is based on an officially noted additive effect that increases the risk of blood dyscrasias.

Altered Exposure and Other Interactions

Pleon is documented to reduce the absorption of certain co-administered substances. This leads to decreased systemic exposure and lower plasma concentrations for the heart medicine Digoxin, and similarly reduces the systemic exposure of the supplement Folic acid.

A population-specific constraint noted in regulatory labeling relates to individuals with N-acetyltransferase (NAT) Poor Metabolizer status. This pharmacogenetic status results in higher systemic levels of a Sulfasalazine metabolite (Sulfapyridine), which is associated with an increased incidence of adverse reactions.

The drug is also documented to interfere with certain laboratory assays, which may cause false-positive readings for urinary normetanephrine and interfere with procedures that measure light absorbance using NAD(H) or NADP(H).

Mechanism of Action

️ How Pleon Works

Pleon's mechanism of action is based on a synergistic engagement of multiple biological domains, modulating metabolic pathways and anti-inflammatory signaling.

Optimizing Cellular Bioenergetics and Anabolic Repair

This mechanism acts as a precursor and co-factor supply system. It engages key transport proteins, like Carnitine Palmitoyltransferase, to facilitate the flux of fatty acid substrates into the TCA cycle, optimizing aerobic ATP generation. Concurrently, it feeds precursors ( Adenine, Orotates) into nucleic acid synthesis, influencing DNA/RNA precursor pools to enable structural maintenance. This provides necessary substrates to influence energy and substrate availability during high-demand states.

Targeted Modulation of Inflammatory Signals

This domain addresses action on specific pro-inflammatory cascades. The mechanism involves the inhibition of enzymes like COX and 5-LO and the modulation of the NF-kappa B pathway. By suppressing the synthesis of potent lipid mediators (prostaglandins and leukotrienes), this component results in a reduction of localized inflammatory mediator synthesis, establishing conditions of attenuated inflammatory signals.

Synergistic Metabolic and Cytoprotective Action

This final mechanism coordinates the two domains: metabolic components modulate the intracellular availability of substrates necessary for repair pathways, while the anti-inflammatory component downregulates the activity of enzymes responsible for generating pro-inflammatory mediators. This allows for a more efficient readjustment of energy and anabolic fluxes.

Dosage and Administration Information

Pleon is a multi-component pharmaceutical preparation administered primarily via the oral route, available in forms such as conventional tablets, delayed-release/enteric-coated tablets, and oral suspension. Rectal formulations may also be used depending on the specific application.

The usage protocol is strictly defined by an initial titration schedule for adults, which mandates starting at a low daily dose (e.g., 0.5 to 1.0 g) and gradually increasing this amount over several weeks. This approach is intended to precede the establishment of the maintenance dose. The standard maintenance dose for chronic inflammatory conditions is typically 2 g daily, administered in divided doses.

The total daily amount is always divided into multiple doses (e.g., two to four times daily). Doses should be taken preferably after meals and must be swallowed with a full glass of water. Specific formulations require careful handling: delayed-release tablets must be swallowed whole and must not be crushed, broken, or chewed. For children aged six years and older, protocols mandate a weight-based dosage calculation, differentiating it from the fixed adult regimen. Treatment is often part of a long-term management plan, with the full response requiring up to 12 weeks for some chronic uses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pleon

Evidence for Symptom Management in Rheumatoid Arthritis (RA)

Research exploring Pleon's role in Rheumatoid Arthritis includes a focus on the anti-inflammatory component, Sulfasalazine. This area of study is supported by numerous Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluate its use in adults with active RA, a condition characterized by fluctuating or episodic manifestations.

Studies examined outcomes related to physical discomfort and daily functioning or activity level. The evidence describes patterns in clinical measurements related to the anti-inflammatory component when studied against placebo or other common therapies. The evidence base for the anti-inflammatory component's use is broadly consistent across various regulatory reviews.

However, the specific clinical value of the full, multi-component Pleon formulation (which includes metabolic and cellular trophic agents) has not been the central focus of the largest efficacy trials. Most core findings describe the anti-inflammatory component alone. Furthermore, there is limited information for long-term outcomes that fully establish the durability of responses beyond the initial intermediate-term follow-up periods (e.g., one year) for the complete combination product.


Evidence for Remission Management in Ulcerative Colitis (UC)

For Ulcerative Colitis, a condition involving periods of heightened symptoms, research has primarily examined the anti-inflammatory component's use in studying changes in disease activity and exploring maintenance of remission. RCTs and subsequent Meta-analyses in both adults and some pediatric groups was studied for how the component performed during active disease and during the maintenance phase.

The main study outcomes examined included the rates at which symptoms were brought under control (remission rates) and the frequency of disease relapse or exacerbation. The research landscape for UC is heavily focused on the anti-inflammatory component. The added necessity or specific clinical contribution of the metabolic and trophic components to symptom control in this condition has not been fully established through dedicated, large-scale clinical research. Data for long-term maintenance outcomes for the full combination are still emerging.


What Remains Uncertain in the Research Landscape

A consistent finding across regulatory reviews is that while the evidence for the anti-inflammatory component is well-established, there are several research limitation frames regarding the complete Pleon formulation:

  • Comparative Evidence: There is limited information from large RCTs that specifically contrast the full seven-component formulation of Pleon against the single anti-inflammatory agent alone to clearly define the added clinical value of the metabolic components.
  • Metabolic Efficacy: Research on the combination of ingredients for systemic support is primarily supported by exploratory studies, and certainty remains low regarding large-scale, definitive outcomes for this aspect of the medicine.

Key Studies & References

  1. Sulfasalazine (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Pleon (FAQ)


Q: What is Pleon actually used for?

According to official regulatory documents, Pleon's key component is indicated for use in treating specific chronic inflammatory conditions. This includes managing ulcerative colitis and certain forms of rheumatoid arthritis. The overall formulation is categorized as providing metabolic support and immunological modulation.


Q: Is Pleon an antibiotic or something else?

Pleon is not classified as an antibiotic. The official classification describes it as a complex multi-component product that functions as a metabolic regulator and a cellular trophic agent. The key component, Sulfasalazine, belongs to the anti-inflammatory and aminosalicylate drug classes.


Q: Does Pleon cause tiredness or drowsiness?

While tiredness or drowsiness are not among the most common adverse effects listed in regulatory documents, dizziness is reported frequently. Due to the presence of central nervous system effects, any unusual or significant fatigue is described as requiring medical consideration.


Q: Is Pleon considered safe for use in older people?

Official documents note that clinical studies did not include enough subjects aged 65 and over to establish definitive differences in response compared to younger adults. Official guidance indicates careful medical consideration for use in older adults due to the potential for higher risk of certain adverse effects.


Q: Why do some people say they stopped taking Pleon?

The most common reasons for patients to stop taking the medication, as noted in clinical trial data, are related to intolerance of common side effects. These frequently reported issues include stomach distress, vomiting, nausea, and headache.


Q: Does Pleon interact with common pain relief medicines like ibuprofen?

Regulatory information indicates that the Sulfasalazine component of Pleon may interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. This combination carries a potential for increased adverse effects, specifically concerning kidney function.


Q: What happens if I forget to take Pleon sometimes?

The official directions for use state that if you miss a dose, you should take it immediately unless it is nearly time for your next scheduled dose. The official directions state not to take two doses to make up for a single missed dose.


Q: What if I drink alcohol while using Pleon?

The official prescribing information does not list a direct prohibition on using alcohol with Pleon. However, alcohol consumption can heighten the risk of certain adverse effects, particularly those related to the gastrointestinal system or liver.


Q: Is Pleon a controlled substance?

Pleon is a prescription-only medication. However, official regulatory agencies do not classify it as a controlled substance.


Q: Are there known interactions between Pleon and birth control pills?

Based on regulatory documentation, the key component in Pleon, Sulfasalazine, has not been shown to interfere with the effectiveness of hormonal birth control pills or other contraceptive methods.


Q: Are there any specific lifestyle changes recommended when taking Pleon?

The official safety profile notes that the key component can cause the skin to be unusually sensitive to sunlight, a condition called photosensitivity. Regulatory information includes an advisory that using sunscreen and wearing protective clothing may be necessary to manage this risk.


Q: Why did the regulatory agency approve Pleon?

Regulatory agencies approve medications based on evidence supporting their intended use and acceptable safety profile. For Pleon, this approval is based on its labeled indications, which include the management of ulcerative colitis and certain forms of arthritis via its key component.


Q: How is Pleon cleared from the body?

The process of clearance involves the breakdown of the key component, Sulfasalazine, primarily in the intestine by bacteria into active metabolites. These substances are then absorbed into the bloodstream, processed further, and eliminated from the body mainly through the urine.


Q: Is Pleon a brand name or a generic name?

Pleon is the brand name used to identify this specific multi-component formulation. Sulfasalazine, which is one of the active ingredients, is the generic drug name.


Q: Do different strengths of Pleon exist?

Pleon is manufactured in multiple dosage forms, including conventional tablets, delayed-release tablets, and an oral suspension. These various forms are provided in specific standardized dose strengths, which a healthcare provider uses to tailor the appropriate regimen.


Q: How long does it take for Pleon to leave your system completely?

The time it takes for Pleon to be completely eliminated from the body is based on the half-life of its key component and metabolites. The half-life for the key component ranges from approximately 7 to 15 hours. Most of the drug is typically cleared from the system after a period equal to four to five times its half-life.


Q: What is the official document called that describes Pleon?

The official, authoritative document that fully describes the medicine, including its uses, safety profile, and administration, is known as the Prescribing Information (PI). In regions outside the US, this is often called the Summary of Product Characteristics (SmPC).


Q: Is Pleon known to cause weight changes?

Anorexia, or loss of appetite, is listed as a very common side effect in the official safety profile. While weight change itself is not listed as a common effect, any significant or unexpected change in body weight is described as requiring medical consideration.


Q: Can I take Pleon if I already take a vitamin supplement?

Official warnings note a potential reduction in folic acid absorption, which may require supplementation. Because drug interactions are complex, official guidance suggests discussing all other supplements with a healthcare provider.


Q: Does Pleon change your mood or mental state?

The official safety data lists common adverse effects such as dizziness and headache. While these are neurological, any unusual or sudden changes in mood or behavior, the official safety data indicates these should be brought to medical attention.


Q: Can Pleon affect my driving ability?

Official warnings advise caution regarding activities that require alertness, such as driving or operating heavy machinery. This is based on the common side effect of dizziness, and regulatory warnings note that an individual's response to the medication should be established before engaging in such activities.


Q: Are there any documented interactions with herbal supplements and Pleon?

While the label does not list specific contraindications with every herbal supplement, official documentation contains guidance suggesting all supplements be discussed with a healthcare provider. This is because complex interactions that could affect safety or effectiveness may occur.

How should Pleon be stored and disposed of?

How to Store and Dispose of Pleon?

Official regulatory guidelines strictly define the storage and disposal requirements for Pleon to maintain product integrity and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C); Keep from freezing.
Protection Store in a dry place and protect from light.
Container Keep in the original container and ensure it is tightly closed.
Safety Keep out of the sight and reach of children.

Disposal Instructions

Do not dispose of Pleon by flushing it down a toilet or pouring it down a sink. Unused or expired medication should be returned to a drug take-back program or disposed of according to local pharmaceutical waste regulations to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pleon found in:

A-Z Index: